PMID- 28910347
OWN - NLM
STAT- MEDLINE
DCOM- 20171012
LR  - 20171012
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 12
IP  - 9
DP  - 2017
TI  - High HPgV replication is associated with improved surrogate markers of HIV
      progression.
PG  - e0184494
LID - 10.1371/journal.pone.0184494 [doi]
AB  - BACKGROUND: Human Pegivirus (HPgV) may have a beneficial effect on HIV disease
      progression in co-infected patients; however, the virologic characteristics of
      this infection are not well defined. In this study, we determined HPgV viremia
      prevalence in Mexico and provide new insights to understand HPgV infection and
      HPgV/HIV co-infection. METHODS: We analyzed and quantified 7,890 serum samples
      for HPgV viremia by One-Step RT-Real-Time PCR, 6,484 from healthy blood donors
      and 1,406 from HIV-infected patients. Data on HIV progression were obtained from 
      patients' records. HPgV genotyping was performed in 445 samples by nested PCR of 
      the 5'URT region. Finite Mixture Models were used to identify clustering patterns
      of HPgV viremia in blood donors and co-infected antiretroviral (ART)-naive
      patients. RESULTS: HPgV was detected in 2.98% of blood donors and 33% of HIV
      patients, with a wide range of viral loads. The most prevalent genotypes were 3
      (58.6%)and 2 (33.7%). HPgV viral loads from healthy blood donors and HPgV/HIV+
      ART-naive co-infected patients were clustered into two component distributions,
      low and high, with a cut-off point of 5.07log10 and 5.06log10, respectively. High
      HPgV viremia was associated with improved surrogate markers of HIV infection,
      independent of the estimated duration of HIV infection or HIV treatment.
      CONCLUSIONS: HPgV prevalence in Mexico was similar to that reported for other
      countries. The prevalent genotypes could be related to Mexico's geographic
      location and ethnicity, since genotype 2 is frequent in the United States and
      Europe and genotype 3 in Asia and Amerindian populations. HPgV viral load
      demonstrated two patterns of replication, low and high. The more pronounced
      beneficial response observed in co-infected patients with high HPgV viremia may
      explain discrepancies found between other studies. Mechanisms explaining high and
      low HPgV replication should be explored to determine whether the persistently
      elevated replication depends on host or viral factors.
FAU - Horemheb-Rubio, Gibran
AU  - Horemheb-Rubio G
AD  - Department of Infectious Diseases, Instituto Nacional de Ciencias Medicas y
      Nutricion Salvador Zubiran, Mexico City, Mexico.
FAU - Ramos-Cervantes, Pilar
AU  - Ramos-Cervantes P
AD  - Department of Infectious Diseases, Instituto Nacional de Ciencias Medicas y
      Nutricion Salvador Zubiran, Mexico City, Mexico.
FAU - Arroyo-Figueroa, Hugo
AU  - Arroyo-Figueroa H
AD  - Department of Infectious Diseases, Instituto Nacional de Ciencias Medicas y
      Nutricion Salvador Zubiran, Mexico City, Mexico.
FAU - Avila-Rios, Santiago
AU  - Avila-Rios S
AD  - Infectious Diseases Research Center, Instituto Nacional de Enfermedades
      Respiratorias, Mexico City, Mexico.
FAU - Garcia-Morales, Claudia
AU  - Garcia-Morales C
AD  - Infectious Diseases Research Center, Instituto Nacional de Enfermedades
      Respiratorias, Mexico City, Mexico.
FAU - Reyes-Teran, Gustavo
AU  - Reyes-Teran G
AD  - Infectious Diseases Research Center, Instituto Nacional de Enfermedades
      Respiratorias, Mexico City, Mexico.
FAU - Escobedo, Galileo
AU  - Escobedo G
AD  - Liver Pancreas and Intestinal Motility Laboratory, Hospital General de Mexico,
      Facultad de Medicina, Universidad Nacional Autonoma de Mexico, Mexico City,
      Mexico.
FAU - Estrada, Gloria
AU  - Estrada G
AD  - Blood Bank, Hospital General de Mexico, Mexico City, Mexico.
FAU - Garcia-Iglesias, Trinidad
AU  - Garcia-Iglesias T
AD  - Immnuology Laboratory, Centro Universitario de Ciencias de la Salud, Universidad 
      de Guadalajara, Guadalajara, Jalisco, Mexico.
FAU - Munoz-Saucedo, Nayeli
AU  - Munoz-Saucedo N
AD  - Immnuology Laboratory, Centro Universitario de Ciencias de la Salud, Universidad 
      de Guadalajara, Guadalajara, Jalisco, Mexico.
FAU - Kershenobich, David
AU  - Kershenobich D
AD  - Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City,
      Mexico.
FAU - Ostrosky-Wegman, Patricia
AU  - Ostrosky-Wegman P
AD  - Biomedical Research Institute, Universidad Nacional Autonoma de Mexico, Mexico
      City, Mexico.
FAU - Ruiz-Palacios, Guillermo M
AU  - Ruiz-Palacios GM
AD  - Department of Infectious Diseases, Instituto Nacional de Ciencias Medicas y
      Nutricion Salvador Zubiran, Mexico City, Mexico.
LA  - eng
PT  - Journal Article
DEP - 20170914
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Biomarkers)
SB  - IM
MH  - Biomarkers/analysis
MH  - CD4 Lymphocyte Count
MH  - Coinfection/*virology
MH  - Disease Progression
MH  - Flaviviridae/genetics/*physiology
MH  - Flaviviridae Infections/*diagnosis/epidemiology/immunology
MH  - Genotype
MH  - HIV Infections/*complications/immunology/virology
MH  - Humans
MH  - Mexico/epidemiology
MH  - Prevalence
MH  - Viral Load
MH  - Viremia/immunology/*virology
MH  - Virus Replication
PMC - PMC5598987
EDAT- 2017/09/15 06:00
MHDA- 2017/10/13 06:00
CRDT- 2017/09/15 06:00
PHST- 2017/05/24 00:00 [received]
PHST- 2017/08/24 00:00 [accepted]
PHST- 2017/09/15 06:00 [entrez]
PHST- 2017/09/15 06:00 [pubmed]
PHST- 2017/10/13 06:00 [medline]
AID - 10.1371/journal.pone.0184494 [doi]
AID - PONE-D-17-19897 [pii]
PST - epublish
SO  - PLoS One. 2017 Sep 14;12(9):e0184494. doi: 10.1371/journal.pone.0184494.
      eCollection 2017.